Dr. Michael Diem has 12 years of global experience in the pharmaceutical & biotechnology industries and currently leads all corporate & business development activities at Amicus. He also has more than 9 years of experience in academic & clinical medicine. Dr. Diem has served in several leadership positions in corporate & business development and has immense background in leading successful BD & licensing activities: mergers & acquisitions; externalization opportunities & divestitures; initiating global opportunities in new areas of business. His expertise in BD is crucial to the success of Amicus’ acquisition of a portfolio of 10 gene therapy programs from Nationwide Children’s Hospital and Celenex. Dr. Diem has a BA in biology, MD from the Rutgers-Robert Wood Johnson Medical School and completed his medical training at Duke University Medical Center. He is a board director at VenatoRx Pharmaceuticals and a board of governors member for the Boys and Girls Clubs of Philadelphia.